泽尼达妥单抗(Zanidatamab) - 药物靶点：HER2_在研适应症：HER2阳性胆道肿瘤，HER2阳性胆管肿瘤，HER2阳性转移性乳腺癌_专利_临床

概要

基本信息

药物类型

双特异性抗体

别名

Zanidatamab (USAN/INN)、Zanidatamab-Hrii、JZP598

+ [4]

靶点

HER2

作用方式

拮抗剂、调节剂

作用机制

HER2拮抗剂(受体蛋白酪氨酸激酶 erbB-2拮抗剂)、免疫调节剂

治疗领域

肿瘤消化系统疾病皮肤和肌肉骨骼疾病+ [5]

在研适应症

HER2阳性胆道肿瘤HER2阳性胆管肿瘤HER2阳性转移性乳腺癌+ [21]

非在研适应症-

原研机构

Zymeworks BC, Inc.

在研机构

Jazz Pharmaceuticals Plc

百济神州（苏州）生物科技有限公司

百济神州（北京）生物科技有限公司

+ [4]

非在研机构-

权益机构

BeiGene Ltd.Zymeworks, Inc.

Pfizer Inc.

+ [2]

最高研发阶段批准上市

首次获批日期

美国 (2024-11-20),

HER2阳性胆道肿瘤

最高研发阶段(中国)批准上市

特殊审评优先审评 (美国)、快速通道 (美国)、孤儿药 (美国)、孤儿药 (欧盟)、优先审评 (中国)、突破性疗法 (中国)、附条件批准 (中国)、加速批准 (美国)、突破性疗法 (美国)

登录后查看时间轴

结构/序列

Sequence Code 528522334

来源: *****

Sequence Code 528522342

来源: *****

Sequence Code 528522349

来源: *****

关联

24

项与泽尼达妥单抗相关的临床试验

NCT06695845

/ Recruiting临床2期

A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206)

The purpose of this study is to evaluate the efficacy and safety of zanidatamab for the treatment of participants with previously treated solid tumors that have Human Epidermal Growth Factor Receptor 2 (HER2) Immunohistochemistry (IHC) 3+ overexpression.

开始日期2025-01-14

申办/合作机构

Jazz Pharmaceuticals Plc

[+1]

NCT06435429

/ Recruiting临床3期

A Phase 3, Randomized, Open-label, Multicenter, Controlled Study to Evaluate the Efficacy and Safety of Zanidatamab in Combination With Physician's Choice Chemotherapy Compared to Trastuzumab in Combination With Physician's Choice Chemotherapy for the Treatment of Participants With Metastatic HER2-positive Breast Cancer Who Have Progressed on, or Are Intolerant to, Previous Trastuzumab Deruxtecan Treatment

The efficacy and safety of zanidatamab in combination with physician's choice of chemotherapy compared with trastuzumab in combination with physician's choice of chemotherapy will be evaluated for the treatment of participants with metastatic HER2-positive breast cancer who have progressed on, or are intolerant to, previous T-DXd treatment.

开始日期2024-08-13

申办/合作机构

Jazz Pharmaceuticals Plc

NCT06282575

/ Recruiting临床3期

An Open-label Randomized Trial of the Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy Alone for Advanced HER2-positive Biliary Tract Cancer

The purpose of this study is to evaluate the efficacy and safety of Zanidatamab plus CisGem (Cisplatin and Gemcitabine) with or without the addition of a programmed death protein 1/ligand-1 (PD-1/L1) inhibitor (physician's choice of either Durvalumab or Pembrolizumab, where approved under local regulations) as first line of treatment for participants with human epidermal growth factor receptor 2 (HER2)-positive biliary tract cancer.

开始日期2024-07-19

申办/合作机构

Jazz Pharmaceuticals Plc

100 项与泽尼达妥单抗相关的临床结果

登录后查看更多信息

100 项与泽尼达妥单抗相关的转化医学

登录后查看更多信息

100 项与泽尼达妥单抗相关的专利（医药）

登录后查看更多信息

27

项与泽尼达妥单抗相关的文献（医药）

2025-12-31·mAbs

Antibodies to watch in 2025

Review

作者: Kapoor, Vaishali ; Kaplon, Hélène ; Crescioli, Silvia ; Visweswaraiah, Jyothsna ; Reichert, Janice M. ; Wang, Lin

The commercial development of antibody therapeutics is a global enterprise involving thousands of biopharmaceutical firms and supporting service organizations. To date, their combined efforts have resulted in over 200 marketed antibody therapeutics and a pipeline of nearly 1,400 investigational product candidates that are undergoing evaluation in clinical studies as treatments for a wide variety of diseases. Here, we discuss key events in antibody therapeutics development that occurred during 2024 and forecast key events related to the late-stage clinical pipeline that may occur in 2025. In particular, we report on 21 antibody therapeutics granted a first approval in at least one country or region during 2024, including bispecific antibodies tarlatamab (IMDELLTRA®), zanidatamab (Ziihera®), zenocutuzumab (BIZENGRI®), odronextamab (Ordspono®), ivonescimab (®), and antibody-drug conjugate (ADC) sacituzumab tirumotecan (®). We also discuss 30 investigational antibody therapeutics for which marketing applications were undergoing review by at least one regulatory agency, as of our last update on December 9, 2024, including ADCs datopotamab deruxtecan, telisotuzumab vedotin, patritumab deruxtecan, trastuzumab botidotin, becotatug vedotin, and trastuzumab rezetecan. Of 178 antibody therapeutics we include in the late-stage pipeline, we summarize key data for 18 for which marketing applications may be submitted by the end of 2025, such as bi- or multispecific antibodies denecimig, sonelokimab, erfonrilimab, and anbenitamab. Key trends in the development and approval of antibody formats such as bispecifics and ADCs, as well as clinical-phase transition and global approval success rates for these antibody formats, are reported.

2025-06-01·EUROPEAN JOURNAL OF CANCER

Real-world efficacy of zanidatamab in patients with HER2 positive advanced biliary tract cancers

Article

作者: Hollebecque, Antoine ; Lancry, Anna ; Vantelon, Jean Marie ; Blanc, Jean-Frédéric ; Decraecker, Marie ; Valery, Marine ; Boileve, Alice ; Klajer, Elodie ; Smolenschi, Cristina ; Debaillon-Vesque, Audrey ; Ducreux, Michel

INTRODUCTION:

In the HERIZON BTC 01 trial for patients with HER2-positive biliary tract cancer (BTC) previously treated with systemic therapy, zanidatamab improved the objective response rate, disease control rate (DCR), progression-free survival (PFS), and overall survival (OS). However, real-world data are needed to assess its efficacy and safety outside clinical trials.

PATIENTS & METHODS:

We conducted an investigator initiated national multicenter retrospective study of most patients with BTC treated with zanidatamab in France as part of a compassionate access. The primary endpoint was PFS.

RESULTS:

Our study included 20 patients with metastatic BTC enrolled between September 2022 and November 2024. The median age at diagnosis was 61.5 (interquartile range: 55-69) years and the majority of patients had gallbladder cancer (n = 12, 60 %). After a median follow-up of 8.5 (95 % confidence interval [CI]: 3.3-11.8) months, the median PFS was 6.7 (95 % CI 1.3-11.8) months, with an estimated OS at 1 year of 79.1 % (95 % CI: 53.2-91.6 %). The DCR was 65 %, with 40 % confirmed partial responses and a median duration of response of 7.3 (95 % CI: 2.06-16) months. Patients with immunohistochemistry (IHC) 3 + HER2 scores had a better PFS [8 (95 % CI: 1.5-18.4) months] than those with 2 + HER2 scores obtained by IHC followed by fluorescence in situ hybridization amplification or next-generation sequencing [1.4 (95 % CI: 1.1-6.8) months] (P = 0.02). No statistical difference in 1-year estimated OS rates was observed (P = 0.39). There were no grade 3 or 4 treatment-related adverse events or cardiac toxicities.

CONCLUSION:

The benefits of in patients with HER2-positive BTC were confirmed. Zanidatamab should be considered for patients with this condition.

2025-05-01·DRUGS

Zanidatamab: First Approval

Review

作者: Keam, Susan J

Zanidatamab (ZIIHERA^®; zanidatamab- hrii), a bi-specific antibody targeting two non-overlapping epitopes of the human epidermal growth factor receptor 2 (HER2) protein, is being developed by Jazz Pharmaceuticals and BeiGene Ltd under license agreements from Zymeworks Inc., the developer of the molecule, for the treatment of HER2-expressing solid tumours. This article summarizes the milestones in the development of zanidatamab leading to this first accelerated approval for use in adults with previously treated, unresectable or metastatic HER2+ (IHC3+) biliary tract cancer (BTC), as detected by an FDA-approved test.

462

项与泽尼达妥单抗相关的新闻（医药）

2 小时之前

·药研网

刚刚！恒瑞HER2 ADC和百济HER2 双抗两款重磅新药国内获批上市！

5月29日，国家药品监督管理局（NMPA）官网显示，恒瑞医药的注射用瑞康曲妥珠单抗（SHR-A1811）和百济神州的HER2双抗泽尼达妥单抗（zanidatamab）相继获批上市。恒瑞注射用SHR-A1811：单药适用于治疗存在 HER2（ERBB2）激活突变且既往接受过至少一种系统治疗的不可切除的局部晚期或转移性非小细胞肺癌（NSCLC）成人患者。百济泽尼达妥单抗：适应症为治疗既往接受过全身治疗的HER2高表达的不可切除局部晚期或转移性胆道癌患者。瑞康曲妥珠单抗：靶向HER2的ADC药物瑞康曲妥珠单抗是一款靶向HER2的抗体偶联药物（ADC），通过结合HER2表达的肿瘤细胞并内吞，在肿瘤细胞内释放毒素，诱导细胞凋亡。此次获批的适应症为存在HER2激活突变且既往接受过至少一种系统治疗的不可切除局部晚期或转移性非小细胞肺癌（NSCLC）成人患者。此前，该药物已有多个适应症获得突破性疗法认定，涵盖HER2阳性的胆道癌、胃癌、结直肠癌、乳腺癌、宫颈癌及卵巢癌等。在2025年AACR年会上公布的I/II期研究（SHR-A1811-I-103）最新数据显示，瑞康曲妥珠单抗在HER2过表达、扩增或突变的转移性NSCLC患者中表现出显著疗效：客观缓解率（ORR）达74.5%，疾病控制率（DCR）高达98.9%；中位缓解持续时间（DoR）为9.8个月，中位无进展生存期（PFS）为11.5个月（IRC评估）；亚组分析显示，疗效在不同患者群体中保持一致，包括基线脑转移患者。泽尼达妥单抗：新型HER2双特异性抗体泽尼达妥单抗是百济神州开发的一款新型HER2双抗，与曲妥珠单抗相比，其在HER2过表达的肿瘤中展现出更强的抗肿瘤活性，甚至对HER2低表达肿瘤也可能有效。此次获批的适应症为既往接受过全身治疗的HER2高表达的不可切除局部晚期或转移性胆道癌患者。2023年ASCO大会公布的IIb期HERIZON-BTC-01研究结果显示：确认的客观缓解率（cORR）为41%，中位缓解持续时间（DOR）达12.9个月；在长期随访中，中位总生存期（OS）达到15.5个月（2024年ASCO数据）；安全性方面，常见不良事件包括腹泻（37%）和输液相关反应（33%），3级及以上不良事件发生率为18%。End声明：本公众号所有发文章(包括原创及转载文章)系出于传递更多信息之目的，且注明来源和作者。本公众号欢迎分享朋友圈或大群，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载/商务/投稿 | 联系微信15618157102（sum_Gmi）商务合作稿件征集点击了解详情往期回顾1集采政策重要拐点22025 AACR 中国ADC创新药物“起飞” | 附资料32025 ASCO热点速递 | 信达、荣昌、科伦集体登场!（附ADC/双/多抗最新进展一览表）

临床结果AACR会议突破性疗法ASCO会议抗体药物偶联物

2 小时之前

·医药观澜

刚刚！百济神州HER2双抗「泽尼达妥单抗」在中国获批上市！

今日（5月29日），中国国家药监局（NMPA）官网最新公示，百济神州申报的1类新药注射用泽尼达妥单抗上市申请已经获得批准，适用于既往接受过全身治疗的HER2高表达（IHC3+）的不可切除局部晚期或转移性胆道癌患者。泽尼达妥单抗（zanidatamab，ZW25）是一种HER2靶向双特异性抗体，可以同时结合两个非重叠的HER2表位。百济神州在2018年与Zymeworks公司达成一项高达约4.3亿美元的授权合作，获得这款产品在亚洲（日本除外）、澳大利亚和新西兰的独家授权。图片来源：NMPA官网截图泽尼达妥单抗可以同时结合两个非重叠的HER2表位。这种独特的设计和增强的结合引发多种作用机制，包括HER2和HER3信号抑制，以及从细胞表面去除HER2蛋白和增强免疫效应功能，如补体依赖性细胞毒性（CDC），从而促进抗肿瘤活性。美国FDA曾授予泽尼达妥单抗突破性疗法认定，用以治疗经治HER2基因扩增胆道癌患者。在中国，该产品已经被CDE纳入突破性治疗品种和优先审评，针对既往接受系统化疗失败的HER2阳性的局部晚期不可切除或转移性胆道癌。2024年11月，FDA宣布加速批准泽尼达妥单抗上市，用于治疗经FDA批准检测确诊为HER2阳性（IHC 3+）的经治无法切除或转移性胆道癌（BTC）成人患者。FDA的加速批准基于HERIZON-BTC-01试验的积极数据。该试验评估了泽尼达妥单抗作为单药用于治疗HER2阳性的经治BTC患者的疗效。HERIZON-BTC-01研究的结果已在2023年美国临床肿瘤学会年会上公布，并发表于The Lancet Oncology。主要疗效结果为根据RECIST v1.1标准，由ICR确定的客观缓解率（ORR）和缓解持续时间（DOR）。研究显示，ORR为52%，ICR评估的中位DOR为14.9个月。本次泽尼达妥单抗在中国获批上市，意味着该产品即将造福更多的胆道癌患者。除了胆道癌适应症，泽尼达妥单抗还正在被开发治疗多种癌症类型，包括HER2阳性结直肠癌（mCRC）、HER2阳性转移性胃食管部腺癌（mGEA）、HER2+胃食管腺癌（GEA）等等。该产品还曾获FDA授予快速通道资格、孤儿药资格，用于治疗胃食管腺癌。参考资料：[1] 国家药监局附条件批准注射用泽尼达妥单抗上市. From https://www.nmpa.gov.cn/zhuanti/cxylqx/cxypxx/20250529142752183.html[2]Zymeworks与百济神州宣布签署HER2靶向治疗候选药物，ZW25和ZW49，在亚太地区的授权协议以及建立Azymetric™和 EFECT™平台的全球研究开发合作关系. Retrieved November 27, 2018, from http://ir.beigene.com/phoenix.zhtml?c=254246&p=irol-newsChi&nyo=0[3] Jazz Pharmaceuticals Announces U.S. FDA Approval of Ziihera® (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract Cancer (BTC). Retrieved Nov 20, 2024, from https://www.prnewswire.com/news-releases/jazz-pharmaceuticals-announces-us-fda-approval-of-ziihera-zanidatamab-hrii-for-the-treatment-of-adults-with-previously-treated-unresectable-or-metastatic-her2-positive-ihc-3-biliary-tract-cancer-btc-302312216.html免责声明：本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。

上市批准优先审批突破性疗法孤儿药快速通道

2 小时之前

·国家药品监督管理局

国家药监局附条件批准注射用泽尼达妥单抗上市

索引号 XZXK-2025-223 主题分类标题国家药监局附条件批准注射用泽尼达妥单抗上市发布日期 2025-05-29近日，国家药品监督管理局通过优先审评审批程序附条件批准百济神州（苏州）生物科技有限公司申报的注射用泽尼达妥单抗（商品名：百赫安）上市，适用于既往接受过全身治疗的HER2高表达（IHC3+）的不可切除局部晚期或转移性胆道癌患者。该品种的上市为相关患者提供了新的治疗选择。

优先审批上市批准

100 项与泽尼达妥单抗相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D12011	-	-	DB15471

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
HER2阳性胆道肿瘤	美国	Jazz Pharmaceuticals, Inc.	2024-11-20
HER2阳性胆道肿瘤	美国	Jazz Pharmaceuticals Ireland Ltd.	2024-11-20

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
HER2阳性胆管肿瘤	申请上市	加拿大	Jazz Pharmaceuticals Plc	2025-04-01
HER2阳性转移性乳腺癌	临床3期	美国	Jazz Pharmaceuticals Plc	2024-08-13
HER2阳性转移性乳腺癌	临床3期	日本	Jazz Pharmaceuticals Plc	2024-08-13
HER2阳性转移性乳腺癌	临床3期	澳大利亚	Jazz Pharmaceuticals Plc	2024-08-13
HER2阳性转移性乳腺癌	临床3期	奥地利	Jazz Pharmaceuticals Plc	2024-08-13
HER2阳性转移性乳腺癌	临床3期	比利时	Jazz Pharmaceuticals Plc	2024-08-13
HER2阳性转移性乳腺癌	临床3期	加拿大	Jazz Pharmaceuticals Plc	2024-08-13
HER2阳性转移性乳腺癌	临床3期	法国	Jazz Pharmaceuticals Plc	2024-08-13
HER2阳性转移性乳腺癌	临床3期	德国	Jazz Pharmaceuticals Plc	2024-08-13
HER2阳性转移性乳腺癌	临床3期	意大利	Jazz Pharmaceuticals Plc	2024-08-13

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02892123 (Phase I trial, ESMO_BC2025)	临床1期	HER2阳性转移性乳腺癌 HER2-expressing	46	Zanidatamab + Paclitaxel	夢觸範網廠築選鑰鹽鹽(簾顧膚襯憲網鏇簾憲鹹) = 膚餘觸鏇鏇繭築膚蓋憲醖憲觸廠膚糧鏇遞蓋範 (蓋願選獵廠觸艱範觸鏇 ) 更多	积极	2025-05-16
NCT02892123 (Phase I trial, ESMO_BC2025)	临床1期	HER2阳性转移性乳腺癌 HER2-expressing	46	Zanidatamab + Capecitabine	夢觸範網廠築選鑰鹽鹽(簾顧膚襯憲網鏇簾憲鹹) = 鬱鏇蓋齋窪範夢範製醖醖憲觸廠膚糧鏇遞蓋範 (蓋願選獵廠觸艱範觸鏇 ) 更多	积极	2025-05-16
NCT04224272 (Pubmed) 人工标引	临床2期	HR阳性/HER2阳性乳腺癌 HER2 Positive \| Hormone Receptor Positive	51	Zanidatamab+palbociclib+fulvestrant	憲遞鹹構網壓醖積夢窪(淵積遞淵範積觸鏇夢糧) = 夢選築築窪繭廠簾夢廠顧淵壓積鬱鬱憲製壓窪 (窪壓夢選願選獵餘願窪 ) 更多	积极	2025-05-05
NCT02892123 \| NCT04466891 (HERIZON-BTC-01, ASCO_GI2025)	临床2期	HER2阳性胆道肿瘤 HER2-expressing	192	Zanidatamab 10 mg/kg QW	製淵醖製觸觸蓋網觸簾(獵膚壓夢觸廠衊夢蓋艱) = 夢範繭糧艱糧廠衊夢觸艱鏇夢壓積遞遞鹽醖糧 (齋構選遞窪鹽觸壓憲積 )	积极	2025-01-23
NCT02892123 \| NCT04466891 (HERIZON-BTC-01, ASCO_GI2025)	临床2期	HER2阳性胆道肿瘤 HER2-expressing	192	Zanidatamab 20 mg/kg Q2W	製淵醖製觸觸蓋網觸簾(獵膚壓夢觸廠衊夢蓋艱) = 繭築艱壓壓餘鹹鬱醖廠艱鏇夢壓積遞遞鹽醖糧 (齋構選遞窪鹽觸壓憲積 )	积极	2025-01-23
NCT04466891 (HERIZON-BTC-01, FDA_CDER) 人工标引	临床2期	HER2阳性胆道肿瘤 HER2 Positive	62	ZIIHERA 20 mg/kg	構繭獵鏇範淵餘鏇遞憲(壓餘鏇顧壓艱齋簾餘憲) = 醖艱齋廠鬱顧網醖積夢襯淵選積網糧醖築網壓 (鑰廠遞積鏇鏇衊壓觸遞, 39 ~ 65) 更多	积极	2024-11-20
NCT04513665 (ZW25-IST-2, CTgov)	临床2期	癌肉瘤 \| HER2表达子宫内膜癌	16	ZW25 (Stage 1)	獵鏇構遞鬱繭築膚衊襯 = 淵鏇艱餘艱糧壓鏇鹹鏇鬱積選網觸獵遞衊獵夢 (觸衊網壓餘觸鏇構淵壓, 襯鬱憲獵鏇觸夢觸齋鑰 ~ 築壓繭廠窪繭醖膚憲製) 更多	-	2024-10-21
NCT04513665 (ZW25-IST-2, CTgov)	临床2期	癌肉瘤 \| HER2表达子宫内膜癌	16	ZW25 (Stage 2)	範製網糧顧夢製觸餘壓(糧繭襯觸憲廠觸蓋鑰獵) = 衊鹽鑰餘廠襯窪範襯範壓壓鹹醖簾壓範壓醖構 (鹽顧糧艱顧襯齋願獵鏇, 顧憲製網艱窪齋積簾夢 ~ 獵餘壓廠簾繭夢糧鏇夢) 更多	-	2024-10-21
NCT03929666 (ESMO2024) 人工标引	临床2期	HER2阳性胃食管腺癌一线 HER2-expressing	46	Zanidatamab + mFOLFOX6	網遞齋範鹽網夢蓋艱觸(範壓夢築窪觸艱鹹範糧) = occurring in ≥5% of all 46 pts enrolled in this study were diarrhoea (35%), hypokalaemia (22%), nausea (7%) and vomiting (7%). Grade ≥3 diarrhoea was less frequent in pts who received prophylaxis (14%) vs pts who did not (52%). 鏇繭憲鑰餘夢膚窪鏇築 (築鏇蓋蓋鑰遞範願鬱糧 ) 更多	积极	2024-09-16
NCT06282575 (HERIZON-BTC-302, ESMO2024)	临床3期	晚期胆管癌一线 HER2-positive	-	Zanidatamab with Cisplatin and Gemcitabine	醖構網構夢築鹽衊窪製(簾簾廠構蓋膚憲範獵膚) = 壓壓淵襯遞範廠齋鏇範鹽獵膚蓋製鹹憲鹽願繭 (膚襯鑰膚夢鹽蓋顧糧齋 )	积极	2024-09-16
NCT04224272 (ZWI-ZW25-202, CTgov)	临床2期	晚期 HER2 阳性乳腺癌	51	Fulvestrant+palbociclib+ZW25 (Zanidatamab)	壓餘鏇顧齋糧築醖願齋 = 窪簾艱遞膚製餘鹹齋選衊淵壓壓遞願鑰糧醖廠 (構製齋醖顧繭鹹網網積, 齋網糧醖範顧醖範繭遞 ~ 糧憲鬱齋膚觸憲願遞鏇) 更多	-	2024-08-14
NCT04466891 (HERIZON-BTC-01, Pubmed \| Future Oncol) 人工标引	临床2期	HER2阳性胆道肿瘤 ERBB2 Amplification	87	Zanidatamab	觸夢醖憲積襯糧構壓窪(餘淵夢鹹選壓築窪選壓) = 積膚廠願窪鏇糧製鑰夢繭夢網鬱艱醖襯簾膚齋 (築顧蓋顧衊淵範築鏇鏇 ) 更多	积极	2024-08-08
NCT04466891 (HERIZON-BTC-01, Pubmed \| Future Oncol) 人工标引	临床2期	HER2阳性胆道肿瘤 ERBB2 Amplification	87	Zanidatamab	淵窪膚鬱窪廠範衊壓襯(構襯衊膚鑰遞襯衊醖壓) = 鹹繭艱鏇鏇遞鹹遞廠積積鹹願襯齋範壓獵網獵 (夢選壓膚遞構繭製範蓋 )	积极	2024-08-08
NCT04466891 \| CTR20202607 (HERIZON-BTC-01, Company_Website) 人工标引	临床2期	HER2阳性胆道肿瘤二线 HER2 Positive	-	Zanidatamab	襯襯獵齋憲夢衊鏇鏇壓(獵觸選選觸膚製齋鹹遞) = 襯鹽鑰淵顧積夢網蓋壓鏇蓋齋壓糧鏇顧夢壓鏇 (觸鹹願願襯窪願餘獵鏇, 30.4–52.8) 更多	积极	2024-06-10